Oral Ifetroban for Idiopathic Pulmonary Fibrosis (IPF)
This study is testing an investigational drug called Ifetroban Sodium for people with Idiopathic Pulmonary Fibrosis (IPF), a chronic lung disease that causes scarring in the lungs. Researchers want to see if taking Ifetroban Sodium once a day by mouth can help improve lung function compared to a placebo (an inactive substance). You might be able to join if you are 40 years or older and have a confirmed diagnosis of IPF. The main goal is to measure changes in your Forced Vital Capacity (FVC), which is how much air you can exhale after a deep breath, over 12 months. The current status of this study is unclear, but it plans to enroll 128 participants.
- Study design
- This is a randomized, placebo-controlled study, meaning participants will be randomly assigned to receive either Ifetroban Sodium or a placebo. It aims to enroll 128 participants.
- What's involved
- Participants will take either oral Ifetroban Sodium or a placebo once daily for 12 months. You will have assessments for safety and efficacy throughout this period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your lung function (FVC) will be measured from the start of the study through 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
At a glance
Conditions
NCT05571059
Where you'd take part
This study runs at 20 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Avera Research Institute
Sioux Falls, South Dakotastudy coordinator listed
Recruiting
Baylor University Medical Center
Dallas, Texasstudy coordinator listed
Recruiting
Beaumont Hospital, Royal Oak
Royal Oak, Michiganstudy coordinator listed
Recruiting
Bend Memorial Hospital
Bend, Oregonstudy coordinator listed
Recruiting
Icahn School of Medicine at Mount Sinai
New York, New Yorkstudy coordinator listed
Recruiting
Indiana University Health
Indianapolis, Indianastudy coordinator listed
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Floridastudy coordinator listed
Recruiting
Miami VA Health System
Miami, Floridastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Todd Rice, MD, MSc · PRINCIPAL_INVESTIGATOR · Cumberland Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from baseline in Forced Vital Capacity (FVC) in mLBaseline through 12 months
To demonstrate a reduction in lung function decline for ifetroban compared to placebo over 52 weeks.